KRYS

Krystal BiotechA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

Probability

Target price

$340.00

+16.0% vs current

Most likely

Base case

Probability

Target price

$305.00

+4.0% vs current

B-

Bear case

Probability

Target price

$225.00

-23.3% vs current

AI sentiment snapshot

Latest data as of 2026-05-04

AI commentary

Tone improved after the May 4, 2026 earnings release: the stock traded at $280.13 at 19:52:17 UTC, about 5.3% above the May 1, 2026 anchor close of $266.04, consistent with a favorable first read on the quarter. Still, this is an early T+1 follow-up with limited confirmed analyst-revision evidence and no usable social packet, so sentiment should be treated as constructive but still monitoring-oriented rather than fully re-underwritten.

RankAlpha Sentiment Codex - 2026-05-04

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-04catalystQ1 earnings beat with profitable VYJUVEK growthMedium impact

Krystal reported Q1 2026 net product revenue of $116.4 million, up 32% year over year, 95% gross margin, and diluted EPS of $1.83; pre-earnings consensus referenced by MarketBeat was about $112.1 million revenue and $1.51 EPS, and KRYS traded at $280.13 on May 4, 2026 versus the May 1, 2026 anchor close of $266.04. Primary support: [#8-K-2026-05-04] [#10-Q-2026-05-04].

2026-12-31eventKB803 and KB801 registrational ophthalmology readouts are the clearest 2026 pipeline unlocksHigh impact

The company said KB803 IOLITE is fully enrolled with top-line results expected in 4Q 2026, while KB801 EMERALD-1 is expected to complete enrollment and announce data before year end; positive readouts would broaden the platform beyond VYJUVEK and support premium valuation. Primary support: [#8-K-2026-05-04].

2026-12-31catalystEx-US VYJUVEK ramp can extend commercial growth but reimbursement timing is unevenHigh impact

Q1 geographic mix showed Europe at $20.7 million and Japan at $8.2 million, with management guiding that German pricing discussions likely run until at least 2H 2026 and France into 2027, while Italy and Spain are potential 2H 2026 launch opportunities. This supports a longer-duration growth path but also keeps reimbursement timing as a gating variable. Primary support: [#8-K-2026-05-04] [#10-Q-2026-05-04].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-04 • Updated nightlySource: Internal modelMethodology